|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2012. View Article : Google Scholar
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zembutsu H: Pharmacogenomics toward
personalized tamoxifen therapy for breast cancer. Pharmacogenomics.
16:287–296. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liu J, Prager-van der Smissen WJ, Look MP,
Sieuwerts AM, Smid M, Meijer-van Gelder ME, Foekens JA, Hollestelle
A and Martens JW: GATA3 mRNA expression, but not mutation,
associates with longer progression-free survival in ER-positive
breast cancer patients treated with first-line tamoxifen for
recurrent disease. Cancer Lett. 376:104–109. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gu Y, Chen T, Li G, Xu C, Xu Z, Zhang J,
He K, Zheng L, Guan Z, Su X, et al: Lower Beclin 1 downregulates
HER2 expression to enhance tamoxifen sensitivity and predicts a
favorable outcome for ER positive breast cancer. Oncotarget.
8:52156–52177. 2016.PubMed/NCBI
|
|
6
|
Reijm EA, Timmermans AM, Look MP,
Meijer-van Gelder ME, Stobbe CK, van Deurzen CH, Martens JW,
Sleijfer S, Foekens JA, Berns PM and Jansen MP: High protein
expression of EZH2 is related to unfavorable outcome to tamoxifen
in metastatic breast cancer. Ann Oncol. 25:2185–2190. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bou Samra E, Klein B, Commes T and Moreaux
J: Development of gene expression-based risk score in
cytogenetically normal acute myeloid leukemia patients. Oncotarget.
3:1–832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Salazar R, Roepman P, Capella G, Moreno V,
Simon I, Dreezen C, Lopez-Doriga A, Santos C, Marijnen C, Westerga
J, et al: Gene expression signature to improve prognosis prediction
of stage II and III colorectal cancer. J Clin Oncol. 29:17–24.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bou Samra E, Klein B, Commes T and Moreaux
J: Identification of a 20-gene expression-based risk score as a
predictor of clinical outcome in chronic lymphocytic leukemia
patients. Biomed Res Int. 2014:4231742014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kim SK, Kim SY, Kim JH, Roh SA, Cho DH,
Kim YS and Kim JC: A nineteen gene-based risk score classifier
predicts prognosis of colorectal cancer patients. Mol Oncol.
8:1653–1666. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robin X, Turck N, Hainard A, Tiberti N,
Lisacek F, Sanchez JC and Müller M: pROC: An open-source package
for R and S+ to analyze and compare ROC curves. BMC Bioinformatics.
12:772011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gao YF, Zhu T, Mao XY, Mao CX, Li L, Yin
JY, Zhou HH and Liu ZQ: Silencing of Forkhead box D1 inhibits
proliferation and migration in glioma cells. Oncol Rep.
37:1196–1202. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gao T, Han Y, Yu L, Ao S, Li Z and Ji J:
CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen
resistance. PLoS One. 9:e917712014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shubbar E, Kovács A, Hajizadeh S, Parris
TZ, Nemes S, Gunnarsdóttir K, Einbeigi Z, Karlsson P and Helou K:
Elevated cyclin B2 expression in invasive breast carcinoma is
associated with unfavorable clinical outcome. BMC Cancer. 13:12013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tan A, Dang Y, Chen G and Mo Z:
Overexpression of the fat mass and obesity associated gene (FTO) in
breast cancer and its clinical implications. Int J Clin Exp Pathol.
8:13405–13410. 2015.PubMed/NCBI
|
|
16
|
Zeng X, Ban Z, Cao J, Zhang W, Chu T, Lei
D and Du Y: Association of FTO mutations with risk and survival of
breast cancer in a Chinese population. Dis Markers.
2015:1010322015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sun T, Fu J, Shen T, Lin X, Liao L, Feng
XH and Xu J: The small c-terminal domain phosphatase 1 inhibits
cancer cell migration and invasion by dephosphorylating
ser(p)68-twist1 to accelerate twist1 protein degradation. J Biol
Chem. 291:11518–11528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Katsyv I, Wang M, Song WM, Zhou X, Zhao Y,
Park S, Zhu J, Zhang B and Irie HY: EPRS is a critical regulator of
cell proliferation and estrogen signaling in ER+ breast cancer.
Oncotarget. 7:69592–69605. 2016.PubMed/NCBI
|
|
19
|
Fu J, Cheng L, Wang Y, Yuan P, Xu X, Ding
L, Zhang H, Jiang K, Song H, Chen Z and Ye Q: The RNA-binding
protein RBPMS1 represses AP-1 signaling and regulates breast cancer
cell proliferation and migration. Biochim Biophys Acta. 1853:1–13.
2015. View Article : Google Scholar : PubMed/NCBI
|
